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Abstract
Background: Left ventricular noncompaction (LVNC) is a rare congenital abnormality. It is currently classified as a
genetic cardiomyopathy and results from early arrest of endomyocardial morphogenesis. The pathophysiology of
left ventricular dysfunction, which becomes apparent beyond the 4th decade of life, is unclear.
Case report: We report a case of 60-year-old woman who presented with shortness of breath and showed
noncompacted endocardium on echocardiography. Cardiac catheterization and viral studies were unremarkable.
Histology revealed endomyocardial fibrosis without disarray. She was subsequently diagnosed with LVNC and
treated with medications.
Discussion: Cardiologists and other physicians should be aware of LVNC due to its high likelihood of misdiagnosis
and associated high complication rates. Early diagnosis, intervention and screening among family members can
decrease the morbidity and mortality associated with LVNC.
Background
Noncompaction of the ventricular myocardium, also
called left ventricular noncompaction (LVNC), is a rare
congenital abnormality seen in only 0.05% of adults [1].
It is characterized by spongy myocardium and results
from arrest of the compaction of the loosely interwoven
meshwork of myocardial fibers during endomyocardial
morphogenesis between 5-8 weeks of fetal life. With the
advent of new diagnostic imaging techniques, more
cases of LVNC are being detected. Early diagnosis is
crucial due to associated high morbidity and mortality.
Case Report
A 60-year-old Caucasian woman with a frequent history of
asthma, presented to the hospital with several weeks of
progressively worsening shortness of breath. She provided
a history of intermittent chest pain which, at one time,
was relieved with nitroglycerin and morphine, given in the
emergency department. As the patient continued having
increasing shortness of breath despite adjustments in her
asthma medications, she was admitted for further workup.
Pertinent positives in her review of systems included
decreased appetite, paroxysmal nocturnal dyspnea, orthop-
nea, lower extremity swelling and intermittent chest pain.
The patient denied fever, chills, or cough. Her past medi-
cal history was significant for type 2 diabetes, asthma, and
osteoarthritis. Medications included theophylline, predni-
sone, furosemide (Lasix), fluticasone & salmeterol (Advair)
and albuterol. She quit smoking 20 years ago and denied
alcohol or intravenous drug abuse. Family history was
negative for coronary artery disease at an early age. The
physical examination was significant for tachycardia, raised
jugular venous pressure, lower extremity edema and
expiratory wheezes upon chest examination.
Laboratory tests revealed elevated brain natriuretic
peptide at 1020 pg/ml (normal <100 pg/ml), and nega-
tive cardiac enzymes with troponin levels consistently
below 0.01 ng/ml (normal 0.00-0.03 ng/ml). Electrocar-
diogram revealed sinus tachycardia, left atrial enlarge-
ment, poor R wave progression and nonspecific ST-T
wave changes in all leads specifically T wave inversion
in the lateral leads (Figure 1). Chest x-ray showed cardi-
omegaly with pulmonary vascular congestion. Pulmon-
ary embolism was ruled out by spiral computer
tomography (CT) scan. A 2D echocardiogram with albu-
min echo contrast showed left ventricular (LV) ejection
fraction of 25-30% with moderate to severe global
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hypokinesis of the left ventricle and moderately enlarged
left atrium. It also showed a normal sized ventricle with
multiple trabeculation in the mid LV cavity and apex
suggesting either an apical form of hypertrophic cardio-
myopathy or LVNC (Figure 2). She underwent cardiac
catheterization which revealed normal coronary arteries.
In view of the normal coronaries and severe global
hypokinesis, further workup was done to rule out other
causes of cardiomyopathy. Viral cultures were negative
for enteric cytopathic human orphan [ECHO] and cox-
sackie viruses. To further elucidate the cause of the car-
diomyopathy, LV endomyocardial biopsy was performed.
Histology showed myocardial fibrosis suggestive of car-
diomyopathy, possibly secondary to LVNC (Figure 3).
Figure 1 A 12-lead electrocardiogram showing sinus tachycardia, left atrial enlargement, poor R wave progression and nonspecific
ST-T wave changes and T wave inversion in the lateral leads.
Figure 2 Transthoracic echocardiogram (A, B, C, D) four
chamber view with albumin contrast showing numerous
trabeculations (white arrow) in the left ventricular apex, along
with deep intertrabecular recesses. (RA- right atrium, LA- Left
atrium, RV-right ventricle, LV- left ventricle).
Figure 3 Endomyocardial biopsy of the left ventricle
(hematoxylin and eosin stain) showing the myocardial fibrosis
(100×, 400×), along with the cardiac myocytes.
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Discussion
Left ventricular noncompaction is a rare cause of cardio-
myopathy, and patients present with systolic dysfunction
commonly of the left, and sometimes of the right ventri-
cle. The incidence of LVNC in clinical practice is low
because it is an under-recognized phenomenon and most
cases are diagnosed as idiopathic cardiomyopathy. Age of
onset and degree of clinical symptoms depend on the
extent of the noncompacted cardiac segments [2].
The exact pathophysiology of the ventricular dysfunc-
tion is not known. Jenni, et al, suggested subendocardial
hypoperfusion and microcirculatory dysfunction in
development of ventricular dysfunction and arrhythmo-
genesis [3]. Echocardiography is the reference standard
for diagnosing LVNC, although it can be well defined by
CT scan, positron emission tomography and magnetic
resonance imaging [4-8]. Echocardiogram shows a two-
layered hypokinetic myocardium with thin, compacted
epicardium, thick, noncompacted endocardium, and a
noncompaction (NC) to compaction (C) ratio >2, and
blood flowing directly from the ventricular cavity in to
the deep intertrabecular recess [2,9]. In this case the
NC/C was >2 with multiple trabeculations and it could
be classified into the prominent trabeculation morpholo-
gical group of LVNC [10].
LVNC is genetically heterogeneous, with predomi-
nance of autosomal dominant inheritance, and is cur-
rently classified under cardiomyopathies as a genetic
disease [11]. LVNC leading to myocardial fibrosis has
not been well defined in the literature [12]. The etiology
of the fibrosis is unclear, but it explains the LV dysfunc-
tion associated with LVNC. Recent studies have
reported a significant prevalence of mitochondrial myo-
pathy and genetic mutations in patients with LVNC.
Myopathies with cardiac involvement have also been
implicated in LVNC, including Barth syndrome, Emery-
Dreifuss muscular dystrophy, and myotubular myopathy
[13,14]. Genetic mutations, especially the alpha-dystro-
brevin gene, Cypher/ZASP and gene G4.5 of the Xq28
chromosome region and loss of the cardiac-specific gene
CSX have been well described in the literature as causes
of LVNC [15-17]. These genetic mutations and myopa-
thies may eventually lead to fibrosis of the myocardium
causing severe LV dysfunction. This process may take
several years, thus explaining why heart failure in
patients with LVNC usually occurs beyond the 4th dec-
ade of life. LVNC is misdiagnosed or missed in a major-
ity of the cases due to its varied presentation and is not
associated with any specific histological finding [18]. In
a small case series, Burke, et al, found that LVNC was
associated with endocardial fibroelastosis and anasto-
mosing or polypoid endocardial trabeculations [19]. In
our case, biopsy showed myocardial fibrosis without any
disarray. Absence of disarray in the histology excluded
hypertrophic cardiomyopathy in this case.
Clinical manifestation of LVNC ranges from absence
of symptoms to disabling congestive heart failure,
arrhythmias, such as atrial fibrillation, ventricular
tachyarrhythmias, and sudden cardiac death, and throm-
boembolic events [20]. LVNC association with neuro-
muscular disorders is commonly seen with Barth
syndrome and mitochondrial disorders [21]. With its
varied presentation and genetic association, patients
diagnosed with LVNC warrant genetic counseling, DNA
diagnostics, and cardiological family screening to make
an early diagnosis and prevent complications [22].
Treatment is symptomatic, including consideration of
heart transplantation. Medical treatment depends mainly
upon the clinical presentation. Cardiac resynchroniza-
tion therapy (CRT) or placement of an implantable car-
dioverter-defibrillators (ICD) should be considered when
the LV ejection fraction ≤35% and prior to heart trans-
plantation. In one study, the largest cohort of LVNC
patients showed the effectiveness of ICD for secondary
or primary prevention of sudden cardiac death, and
improvement of New York Heart Association (NYHA)
class in patients with LV ejection fraction ≤35% or
LVNC with CRT [23]. There are no concrete guidelines
for anticoagulation therapy as a primary prevention of
thromboembolism among LVNC patients. Many authors
believe that it should be considered among LVNC
patients with atrial fibrillation, severe LV dysfunction, or
a history of thromboembolism. In our case, implantation
of an ICD, warfarin anticoagulation was offered to the
patient but she refused.
Prognosis, in general, is poor and improves signifi-
cantly with heart transplantation. A larger case series of
34 patients with long-term follow-up of 44 months,
showed mortality of 35%, and with sudden cardiac death
accounting for 50% of fatalities [2]. In the same study,
24% of patients had thromboembolic events and 41%
had ventricular tachyarrhythmias. A recent similar study
showed lower mortality and fewer complications [24].
This variation is secondary to the inclusion of milder/
preclinical cases in the later study, along with advance-
ment in the echocardiographic technology that facilitate
earlier diagnosis. Heart transplantation is considered
only when medical therapy fails to control the progres-
sion of heart failure. Our patient responded well to
treatment with angiotensin-converting enzyme inhibitors
and beta blockers.
Conclusion
Cardiologists and other physicians should be aware of
LVNC due to its high likelihood of misdiagnosis and
consequent high complication rates. Early diagnosis and
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intervention, and screening among family members can
decrease the morbidity and mortality associated with
LVNC.
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